177 related articles for article (PubMed ID: 25577805)
1. [First-line chemotherapy for unresectable and metastatic colorectal cancer].
Satoh T
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1372-5. PubMed ID: 25577805
[No Abstract] [Full Text] [Related]
2. Maintenance therapy in metastatic colorectal cancer.
Marshall JL
Clin Adv Hematol Oncol; 2014 Jun; 12(6):388-90. PubMed ID: 25003569
[No Abstract] [Full Text] [Related]
3. First-line treatment options for patients with metastatic colorectal cancer.
Schilsky RL
Nat Clin Pract Oncol; 2004 Dec; 1(2):70-1. PubMed ID: 16264820
[No Abstract] [Full Text] [Related]
4. Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer.
Yoshida M; Goto M; Kii T; Nishitani H; Kawabe S; Kuwakado S; Asaishi K; Miyamoto T; Higuchi K
Digestion; 2013; 87(1):59-64. PubMed ID: 23343971
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab in the treatment of colorectal cancer.
Goldberg RM; Venook AP; Schilsky RL
Clin Adv Hematol Oncol; 2004 Nov; 2(11):1-10; quiz 11-12. PubMed ID: 16170891
[No Abstract] [Full Text] [Related]
6. Progression-free survival in bevacizumab-based first-line treatment for patients with metastatic colorectal cancer: is it a really good end point?
Montagnani F; Migali C; Fiorentini G
J Clin Oncol; 2009 Oct; 27(28):e132-3; author reply e134-5. PubMed ID: 19720898
[No Abstract] [Full Text] [Related]
7. Optimizing oxaliplatin-based therapy in metastatic colorectal cancer.
Cassidy J
Clin Adv Hematol Oncol; 2008 May; 6(5):360-1. PubMed ID: 18516025
[No Abstract] [Full Text] [Related]
8. Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials.
O'Neil BH; Goldberg RM
Oncologist; 2008 Oct; 13(10):1074-83. PubMed ID: 18922828
[TBL] [Abstract][Full Text] [Related]
9. Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy: Evaluation of Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845-52.
Bruera G; Ricevuto E
Expert Opin Biol Ther; 2011 Jun; 11(6):821-4. PubMed ID: 21545334
[TBL] [Abstract][Full Text] [Related]
10. Emerging phase 3 data in relapsed/refractory metastatic colorectal cancer.
Goldberg R
Clin Adv Hematol Oncol; 2016 Jan; 14(1):30-3. PubMed ID: 27057664
[No Abstract] [Full Text] [Related]
11. Evolution of systemic therapy for metastatic colorectal cancer.
Geh JI; Ma YT
Colorectal Dis; 2011 Aug; 13(8):852-4. PubMed ID: 21762349
[No Abstract] [Full Text] [Related]
12. Benefit of FOLFOX to unresectable liver metastases secondary from colorectal carcinoma in an oncologic emergency.
Sugimoto M; Yasuda H; Koda K; Yamazaki M; Tezuka T; Takenoue T; Kosugi C; Higuchi R; Yamamoto S; Watayo Y; Yagawa Y; Suzuki M
Hepatogastroenterology; 2007 Sep; 54(78):1684-8. PubMed ID: 18019695
[TBL] [Abstract][Full Text] [Related]
13. Metastatic colorectal cancer: treatment challenges and quality of life.
Bottomley A
Lancet; 2002 May; 359(9317):1537-8. PubMed ID: 12047959
[No Abstract] [Full Text] [Related]
14. Optimal treatment of metastatic colorectal cancer.
Pessino A; Sobrero A
Expert Rev Anticancer Ther; 2006 May; 6(5):801-12. PubMed ID: 16759170
[TBL] [Abstract][Full Text] [Related]
15. Clinical Trial Data for Third-Line Therapy in Metastatic Colorectal Cancer.
Bekaii-Saab T
Clin Adv Hematol Oncol; 2019 Mar; 17 Suppl 7(3):5-13. PubMed ID: 31730590
[No Abstract] [Full Text] [Related]
16. Molecularly targeted therapy: toxicity and quality of life considerations in advanced colorectal cancer.
Ribecco AS; Pino MS; Cipriani G; Marinozzi C; Fioretto L
Expert Rev Anticancer Ther; 2013 Oct; 13(10):1181-91. PubMed ID: 24134420
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of monthly chemotherapy for patients with unresectable metastatic colorectal cancer.
Tomoda M; Kawahara H; Watanabe K; Enomoto H; Akiba T; Yanaga K
Anticancer Res; 2014 Jan; 34(1):191-4. PubMed ID: 24403461
[TBL] [Abstract][Full Text] [Related]
18. Directions for further improvements of treatment of metastatic colorectal cancer.
Brünner N; Nielsen HJ
Scand J Gastroenterol; 2012 Mar; 47(3):363-4. PubMed ID: 22181055
[No Abstract] [Full Text] [Related]
19. Third-line therapy for metastatic colorectal cancer.
Gundgaard MG; Soerensen JB; Ehrnrooth E
Cancer Chemother Pharmacol; 2008 Jan; 61(1):1-13. PubMed ID: 17786445
[TBL] [Abstract][Full Text] [Related]
20. Oral anti-angiogenesis treatment plus chemotherapy is not more efficacious than bevacizumab plus chemotherapy in metastatic colorectal cancer.
Oncology (Williston Park); 2011 Nov; 25(12):1232. PubMed ID: 22229221
[No Abstract] [Full Text] [Related]
[Next] [New Search]
